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Abstract
We report a patient with empyema in the setting of an unre-
solved Streptococcus anginosus pneumonia for over a month
after two courses of antimicrobial treatment. A chest com-
puted tomography (CT) revealed a localized pleural fluid col-
lection. The pleural fluid cultures grew S. anginosus resis-
tant to clindamycin and erythromycin. The patient was treated
with ampicillin-sulbactam plus surgical interventions. Initially,
the patient underwent CT-guided placement of chest tube
with instillation of tissue plasminogen activator. Subsequently,
he required a video-assisted thoracoscopy with decortication
and drainage of empyema, followed by a remarkable improve-
ment in his overall condition. Our case highlights the infec-
tions caused by the Streptococcus milleri group (SMG) in indi-
viduals with an unresolved pneumonia. Such patients should
be diagnosed accurately and treated aggressively with rapid
and effective interventions.
Introduction
Streptococci milleri group (SMG) have been known to
cause purulent infections.[1] They are commensal or-
ganisms found in the mucosa lining the oral cavity,
oropharynx, gastrointestinal tracts and genitourinary
tracts in both adults and children.[2] These organisms
have been known to cause periodontal abscess.[2, 3]
They are commonly associated with both monomicro-
bial and polymicrobial infections. Monomicrobial in-
fections are more common in head and neck infec-
tions while gastrointestinal infections are polymicro-
bial in nature involving anaerobes.[2, 4] Anaerobic or-
ganisms found in the polymicrobial infection have been
reported to enhance SMG infections.[4–7] Streptococcus
anginosus is strongly associated with infections of the
skin and soft tissue, as well as gastrointestinal and gen-
itourinary infections.[6] These organisms are unique
in their ability to form abscess, which differentiates
them from S. pyogenes and S. agalactaciae.[3] Most of-
ten, these organisms have been implicated in causing
parapneumonic effusions and abscess.[8, 9] Identifica-
tion of these organisms is essential for timely diagno-
sis, and aggressive treatment is required. We describe
a case of empyema caused by SMG in a patient with an
unresolved left-sided pneumonia.
Case Report
A 37-year-old Caucasian male was evaluated in the
emergency room (ER) for 4–6 weeks of cough, white
sputum, shortness of breath, and weight loss. A month
prior to his current presentation, he was diagnosed
with radiologically confirmed left lower lobar pneumo-
nia (Figure 1) and was treated with a 4-day course of
250 mg of azithromycin as an outpatient. A month after
the initial presentation, he reported similar complaints
and was prescribed 100 mg twice a day of doxycycline
for 28 days. The patient has worked as a gravedig-
ger for 14 years. He smoked one pack of cigarettes per
day over the last 20 years and had no history of alcohol
abuse. His medical history was significant for chronic
bronchitis and adenomatous colonic polyps diagnosed
in the past year.
On physical examination, he had decreased breath
sounds in the left middle and lower lung fields. Ini-
tial workup revealed a white blood cell count (WBC) of
18,210 cells/mm3. A chest computed tomography (CT)
showed a left-sided pleural effusion and compressive
atelectasis of the left lung, consistent with empyema
(Figure 2). He was admitted to the hospital for fur-
ther management. He underwent CT-guided place-
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Figure 1. Chest X-ray done prior to hospital admission showed left lower lobe pneumonia.
Figure 2. Computerized tomography of the chest at hospital admission shows left base pleural collection suggestive of empyema.
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ment of pleural catheter with tissue plasminogen acti-
vator (TPA) irrigation for the drainage of pleural fluid
during the first 3 days of his admission. A follow-up
chest X-ray at day 3 of hospitalization showed a reduc-
tion in the fluid collection with persistence of left-sided
complicated effusion. A panoramic mandibular X-ray
was performed due to his poor dentition, showing no
findings of periapical abscess. The microbiological cul-
tures of blood and sputum were negative; however, at
day 4 of his admission, pleural fluid cultures grew S.
anginosus, which was resistant to clindamycin and ery-
thromycin (Table 1). Due to the presence of signifi-
cant fluid on subsequent radiological studies, he un-
derwent video-Assisted thoracoscopic surgery (VATS)
with lateral decortication and drainage of empyema
with placement of a chest tube on day 7 of the hospital-
ization. A subsequent CT showed improved atelectasis
and consolidation in the left middle and lower lobes
(Figure 3). The pleural fluid cytology and histopatho-
logical analysis excluded malignancy. The patient was
started on intravenous (IV) ampicillin-sulbactam 3 mg
every 6 hours from day 2 of hospitalization until day
12. He was switched to 500 mg of oral amoxicillin dur-
ing the last two days of his hospitalization and was pre-
scribed the same for an additional five days after being
discharged. The patient improved clinically and was
discharged on day 14 of hospitalization. The patient
continued to show remarkable marked improvement
during subsequent outpatient follow-up appointments.
A radiological assessment three months after his ad-
mission to the hospital showed complete resolution of
the left-sided empyema (Figure 4).
Discussion
We herein present a case of pleural empyema caused
by S. anginosus in a young patient with an unresolved
pneumonia. Since the SMG are not the most common
pathogens known to cause empyema in the United
States, it is important to suspect them in patients who
do not improve on empiric antibiotic therapy.[10]
Pleural empyema is a bacterial infection resulting in
the formation of pus in the pleural cavity.[10] It is
an uncommon complication of community-acquired
pneumonia (CAP), with approximately 32,000 cases per
year in the United States. Around 20 percent of pa-
tients with pneumonia develop a parapneumonic ef-
fusion, which may lead to empyema.[11] The mean
time for the development of empyema has been re-
ported as 18 days.[8, 12] Empyema can be due to un-
treated pneumonia. Accumulation of frank pus and mi-
crobes in the pleural cavity leads to the development of
empyema.[13] The pleural infection can be divided into
three stages. Stage 1 is the exudative phase, which is
characterized by the accumulation of clear fluid. This is
a simple parapneumonic effusion due to the inflamma-
tion caused by the pneumonia. During Stage 2, the sim-
ple effusion may undergo fibrinopurulent deposition,
triggered by bacterial invasion leading to the formation
of empyema. At Stage 3, there is a widespread scar-
ring and pleural peeling, causing restriction of lung re-
expansion. Increasing prevalence of empyema caused
by SMG bacteria should raise concern among clini-
cians. The predisposing factors for SMG empyema
include old age (median ages 60-68), mucosal distur-
bance (e.g., sinusitis, periodontal abscess), excessive al-
cohol consumption, diabetes mellitus, previous surgi-
cal procedures involving instrumentation in the tho-
rax, enteric diseases (e.g., esophageal perforation) and
immunosuppressive states, such as malignancy.[4, 5,
9, 14] Cases of pleural empyema have also been de-
scribed in young patients with none of these risk fac-
tors.[10] The patient in our study was young and had
non-resolving pneumonia as a risk factor. A case se-
ries of 25 patients found that pneumonia was a predis-
posing factor in around 40 percent of patients who de-
veloped SMG empyema, thereby stressing the role of
these organisms in pulmonary infections.[8] According
to another study, pleural effusion was reported in 54.5
percent of patients with SMG infections. The study also
found that pleural effusion was more commonly asso-
ciated with SMG infection than infections caused by
other pathogens, including but not limited to S. pneu-
moniae.[15] Our patient also initially presented with a
loculated empyema, which was consistent with previ-
ously reported cases. Although our patient had poor
dentition on an oral examination, he did not have any
periodontal abscess, which was unique since dental ab-
scess was found to be associated with 40 percent of pa-
tients with SMG empyema.[4] Therefore, thorough oral
examination should be conducted in suspected cases.
Since SMG are not commonly considered pathogens
when evaluating patients for sputum culture, it is often
difficult to distinguish them from contaminants. There-
fore, physicians must assess the patients who have a
positive sputum bacterial culture carefully.
SMG empyema should be treated aggressively with an-
timicrobial drugs in combination with surgical inter-
ventions. The antimicrobial therapy may be guided
by susceptibility studies. SMG are generally suscep-
tible to beta-lactam agents. Commonly used agents
include penicillin, ampicillin, and cephalosporin. For
those allergic to penicillin, erythromycin, clindamycin
or vancomycin could be used as alternatives.[4, 5]
However, cases of resistance to erythromycin and clin-
damycin have been reported, consistent with our case
report.[16] The antibiotics showing 100 percent suscep-
tibility are vancomycin, imipenem and teicoplanin.[13]
Amoxicillin-clavulanic acid can be used in cases of
polymicrobial infection.[3] Our patient was treated
with IV ampicillin-sulbactam during the course of
his hospitalization and was prescribed amoxicillin-
clavulanic acid at the time of discharge to ensure ad-
equate coverage. Inadequate treatment with antimicro-
bials during the acute phase leads to the progression
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Table 1. Table showing antibiotic susceptibility of Streptococcus angi-








Figure 3. Follow-up chest X-ray imaging done post-VATS on day 7 of hospitalization showed reduction in size of opacity in left hemithorax.
ULJRI | https://ir.library.louisville.edu/jri/vol5/iss1/14 4
ULJRI SMG Empyema and Lung Infection
Figure 4. Follow-up computerized tomography of the chest 3 months after hospital admission showed complete resolution of left-sided empyema.
of empyema.[17] The duration of antimicrobial therapy
may be variable; however, a minimum of 2 weeks of
antibacterial therapy from the time of drainage and de-
fervescence is recommended.[18] Antimicrobial treat-
ment alone is not recommended for empyema since
there is a wide fluctuation in antibiotic penetration
into the abscesses, independent of the dosage given.[8,
9] Empyema often requires drainage.[13] Intrapleural
instillation of streptokinase enhances the clearance of
pleural cavity and could be used in the management
of effusions and empyema.[4] Complete drainage of
empyema in the acute phase is important in achiev-
ing re-expansion of atelectasis and obtaining a satisfac-
tory outcome.[17] The majority of the SMG empyema
require surgical intervention for definitive therapy.
Hence, they should be considered for early operative
intervention due to the unrelenting nature of the in-
fection. Early surgical intervention is associated with
shorter duration of hospitalization, decreased mortal-
ity [1] and favorable outcomes in patients with SMG
respiratory infection. Thoracocentesis is useful in the
management of uncomplicated pleural effusion (Stage
1) and helps in the diagnosis of complicated effusion.
VATS decortication is a feasible and effective proce-
dure for the treatment of empyema refractory to con-
ventional therapy.[19] VATS is the first-line approach
in all patients with Stage 2 or Stage 3 empyema who
can tolerate single-lung ventilation. However, tho-
racotomy is recommended for patients who may not
be able to tolerate single-lung ventilation or continue
to have recurrence. Patients with chronic empyema
are treated through surgical interventions, as opposed
to pleural drainage procedures, since complete evac-
uation of pleural space followed by obliteration of
empyema plays a key role in preventing recurrence.
These patients may be treated with VATS or open thora-
cotomy. Open thoracic window and marsupialization
of infected thoracic cavity with resection of several ribs
and dressing changes is performed in patients who are
medically unfit to tolerate VATS or decortication pro-
cedures.[18] Despite undergoing pleural drainage in-
terventions during the initial course of his hospitaliza-
tion, our patient underwent VATS subsequently due to
the recurrence of fluid collection, as evident in radio-
logical assessments. Delay in diagnosis, failure to insti-
tute appropriate antimicrobial therapy and inadequate
drainage contribute to increased morbidity and mor-
tality.[13, 17] Aggressive management with rapid and
effective intervention can help to reduce in-hospital
mortality, morbidity, and duration of hospital stay and
tends to result in overall good long-term outcomes.[13,
17]
Conclusion
In conclusion, S. anginosus empyema should be sus-
pected in any patient with unresolved respiratory in-
fection not responding to empirical antibiotic therapies,
consolidation on repeated radiological imaging and a
possible history of odontogenic infection. Taking a
careful history, performing a thorough physical exam,
and managing the infection aggressively with appro-
priate antibiotics, drainage and, if required, surgical de-
bridement is essential to ensure resolution.
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